Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY16 Outlook
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.68, $0.03 better than the analyst estimate of $1.65. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.71 billion.
Xarelto revenue $529 million, versus $564 million expected.
Imbruvica revenue $349 million, estimate at $313 million.
J&J now sees FY16 adjusted EPS of $6.68 - $6.73, versus an expected range of $6.63 - $6.73 prior and compared with the current consensus of $6.69. Sales guidance was maintained.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Corelogic (CLGX) Tops Q3 EPS by 7c, Expects to Achieve Upper Ends of FY16 Guidance
- Agree Realty (ADC) Tops Q3 FFO by 4c
- e-Future Information Technology (EFUT) Reports Q3 Loss of RMB0.75/Share
Create E-mail Alert Related CategoriesEarnings, Guidance, Hot Earnings, Hot Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!